Extended Data Fig. 5: NTD inhibitor EPI001 exhibits weak inhibition on condensates of AR resistant mutations.
From: Targeting androgen receptor phase separation to overcome antiandrogen resistance
a. Living-cell imaging of LNCaP cells expressing AR(WT), AR(T878A), AR(W742C) and AR(F877L/T878A)-EGFP treated with EPI001 upon DHT stimulation. Scale bar, 2.5 μm. b. Box plot showing puncta number in LNCaP cells expressing AR(WT), AR(T878A), AR(W742C) and AR(F877L/T878A)-EGFP treated with EPI001 in the absence/presence of DHT (N = 50–100 cells). c. Transactivation reporter (ARE) assays of HEK293T cells expressing AR(WT), AR(T878A), AR(W742C) and AR(F877L/T878A) treated with EPI001 in the absence/presence of DHT. Data are presented as the mean ± SD, n = 3 biologically independent samples per group.
